These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23857878)

  • 41. The prevalence of QT prolongation in a population of patients with substance use disorders.
    Scott AJ; Dunlop AJ; Brown A; Sadler C; Isbister GK
    Drug Alcohol Rev; 2017 Mar; 36(2):239-244. PubMed ID: 27241860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.
    Freeman BD; Dixon DJ; Coopersmith CM; Zehnbauer BA; Buchman TG
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):971-81. PubMed ID: 18693297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimization of the adult zebrafish ECG method for assessment of drug-induced QTc prolongation.
    Chaudhari GH; Chennubhotla KS; Chatti K; Kulkarni P
    J Pharmacol Toxicol Methods; 2013; 67(2):115-20. PubMed ID: 23353637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals.
    Tashibu H; Miyazaki H; Aoki K; Akie Y; Yamamoto K
    J Pharmacol Sci; 2005; 99(5):473-86. PubMed ID: 16493188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation.
    Miyazaki H; Watanabe H; Kitayama T; Nishida M; Nishi Y; Sekiya K; Suganami H; Yamamoto K
    J Pharmacol Sci; 2005; 99(5):523-9. PubMed ID: 16493192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prolongation of QT interval and evaluation of safety of drugs].
    Li Y; Xu J; Zhang W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Aug; 30(4):905-8. PubMed ID: 24059079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram.
    Pae CU; Wang SM; Lee SJ; Han C; Patkar AA; Masand PS
    Expert Opin Drug Saf; 2014 Feb; 13(2):197-205. PubMed ID: 24131458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
    Chastang A; Renet S; Corny J; Beaussier H; Petre A; Lillo-Lelouet A; Phan Thi TT; Bézie Y
    Int J Clin Pharm; 2019 Feb; 41(1):42-48. PubMed ID: 30610545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis.
    Tsamandouras N; Duvvuri S; Riley S
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):605-616. PubMed ID: 31664592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Translating QT interval prolongation from conscious dogs to humans.
    Dubois VF; Smania G; Yu H; Graf R; Chain AS; Danhof M; Della Pasqua O; ;
    Br J Clin Pharmacol; 2017 Feb; 83(2):349-362. PubMed ID: 27614058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.
    De Ponti F; Poluzzi E; Vaccheri A; Bergman U; Bjerrum L; Ferguson J; Frenz KJ; McManus P; Schubert I; Selke G; Terzis-Vaslamatzis G; Montanaro N
    Br J Clin Pharmacol; 2002 Aug; 54(2):171-7. PubMed ID: 12207637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Ondansetron on QT Interval in Patients Cared for in the PICU.
    Trivedi S; Schiltz B; Kanipakam R; Bos JM; Ackerman MJ; Ouellette Y
    Pediatr Crit Care Med; 2016 Jul; 17(7):e317-23. PubMed ID: 27387786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14.
    Darpo B; Garnett C; Keirns J; Stockbridge N
    Drug Saf; 2015 Sep; 38(9):773-80. PubMed ID: 26162419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling.
    Warnier MJ; Holtkamp FA; Rutten FH; Hoes AW; de Boer A; Mol PG; De Bruin ML
    Drug Discov Today; 2014 Sep; 19(9):1294-7. PubMed ID: 24973646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.
    Niemeijer MN; van den Berg ME; Eijgelsheim M; Rijnbeek PR; Stricker BH
    Drug Saf; 2015 Oct; 38(10):855-67. PubMed ID: 26108299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation.
    Milan DJ; Jones IL; Ellinor PT; MacRae CA
    Am J Physiol Heart Circ Physiol; 2006 Jul; 291(1):H269-73. PubMed ID: 16489111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of drug-related QT prolongation on FDA regulatory decisions.
    Park E; Willard J; Bi D; Fiszman M; Kozeli D; Koerner J
    Int J Cardiol; 2013 Oct; 168(5):4975-6. PubMed ID: 23920061
    [No Abstract]   [Full Text] [Related]  

  • 58. A NOS1AP gene variant is associated with a paradoxical increase of the QT-interval shortening effect of digoxin.
    Soroush N; Aarnoudse AJ; Kavousi M; Kors JA; Ikram MA; Newton-Cheh C; Ahmadizar F; Stricker BH
    Pharmacogenomics J; 2022 Feb; 22(1):55-61. PubMed ID: 34616002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Racial susceptibility for QT prolongation in acute drug overdoses.
    Manini AF; Stimmel B; Vlahov D
    J Electrocardiol; 2014; 47(2):244-50. PubMed ID: 24438862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies.
    Guth BD; Bass AS; Briscoe R; Chivers S; Markert M; Siegl PK; Valentin JP
    J Pharmacol Toxicol Methods; 2009; 60(2):107-16. PubMed ID: 19470407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.